D.Western Therapeutics Institute (6DW) Stock Price & Analysis
6DW Stock Chart & Stats
- Day’s Range
- EUR 0.29 - EUR 0.29
- 52-Week Range
- EUR 0.29 - EUR 0.55
- Previous Close
- EUR 0.30
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 19.28M
- Enterprise Value
- EUR 3.25B
- Total Cash (Recent Filing)
- EUR 1.54B
- Total Debt (Recent Filing)
- EUR 594.17M
- Price to Earnings (P/E)
- ―
- Beta
- -0.49
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
Very strong gross margins indicate that the company’s drug-discovery activities can retain substantial value after direct costs. If revenue stabilizes or successful candidates generate broader commercial income, this margin structure could support operating leverage and improve future earnings potential.
Narrowing Losses
The reduction in losses shows progress toward improving operating economics, even though the company remains far from break-even. Continued cost discipline or stronger development-related revenue could allow this improvement to compound and reduce the scale of future funding needs.
Improved Leverage
The sharp reduction in debt-to-equity provides a more manageable capital structure and improves financial flexibility relative to the prior year. Lower leverage can reduce balance-sheet pressure while giving the company greater capacity to pursue development activities or absorb operating volatility.
Bears Say
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not currently self-funding its operations or development pipeline. Even though the burn improved in 2025, continued cash consumption can require external financing and may constrain investment in future growth.
Deep Operating Losses
Losses that exceed revenue demonstrate that the company remains structurally unprofitable despite its strong gross margin. Persistent operating deficits can consume equity, limit internally funded research, and make financial performance dependent on achieving future development or partnership milestones.
Volatile Declining Revenue
Small and fluctuating revenue creates limited visibility into the company’s ability to build a durable commercial base. A further decline would make it harder to absorb fixed research and operating costs, prolong the path to break-even, and reinforce reliance on external capital.
D.Western Therapeutics Institute News
6DW FAQ
What was D.Western Therapeutics Institute’s price range in the past 12 months?
What is D.Western Therapeutics Institute’s market cap?
When is D.Western Therapeutics Institute’s upcoming earnings report date?
How were D.Western Therapeutics Institute’s earnings last quarter?
Is D.Western Therapeutics Institute overvalued?
Does D.Western Therapeutics Institute pay dividends?
What is D.Western Therapeutics Institute’s EPS estimate?
How many shares outstanding does D.Western Therapeutics Institute have?
What happened to D.Western Therapeutics Institute’s price movement after its last earnings report?
Which hedge fund is a major shareholder of D.Western Therapeutics Institute?
What is the TipRanks Smart Score and how is it calculated?
Company Description
D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yuichi Hidaka
- Employees
- 19
- Website
- www.dwti.co.jp
- Address
- CK21 Hirokoujifushimi Bldg., Nagoya, AI, 460-0003, JP
D.Western Therapeutics Institute (6DW) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
